Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China

Deal Overview:
Sanofi has acquired exclusive rights to develop and commercialize aficamten, a cardiac myosin inhibitor, from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China13.

Financial Terms:
Cytokinetics is eligible to receive up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties in the low-to-high teens on future sales of aficamten in Greater China13.

Clinical Development:
Aficamten has been granted Breakthrough Therapy Designation for symptomatic obstructive HCM by the China National Medical Products Administration and has a New Drug Application accepted for priority review1.

Market Potential:
Analysts have pegged peak global sales of aficamten at $3 billion, making it a potential blockbuster drug for Cytokinetics4.

Strategic Partnership:
The partnership leverages Sanofi's cardiovascular expertise and resources to advance aficamten's commercial prospects in a key market, aligning with Cytokinetics' goal of expanding the drug's reach to HCM patients in Greater China14.

Sources:

1. https://www.investing.com/news/stock-market-news/cytokinetics-stock-rises-on-sanofis-rights-acquisition-93CH-3785170

3. https://www.marketscreener.com/quote/stock/CYTOKINETICS-INCORPORATED-13479846/news/Cytokinetics-Incorporated-Announces-Sanofi-Acquires-Exclusive-Rights-to-Develop-and-Commercialize-A-48632695/

4. https://www.bizjournals.com/sanfrancisco/news/2024/12/23/china-heart-drug-sanofi-cytokinetics-aficamten.html